Bristol-Myers Squibb Reports Strong Q2 2026 Results and Raises Full-Year Outlook

Details

The company reported GAAP EPS of $1.62 and non-GAAP EPS of $2.04. The company raised its full-year revenue guidance to a range of $49.0 billion to $50.0 billion and increased its non-GAAP EPS range to $6.75 to $7.00. Key product highlights include significant growth in Opdivo, Reblozyl, Breyanzi, and Camzyos. The company also announced positive updates on its pipeline, including FDA acceptances for Reblozyl and mezigdomide.

Items reported

About Bristol-Myers Squibb Company

Bristol-Myers Squibb Company is a renowned pharmaceutical corporation engaged in the discovery, development, and distribution of innovative medicines. The company's core focus lies in providing therapeutic solutions for areas such as oncology, immunology, cardiovascular disease, and fibrotic diseases. Founded in 1887 and headquartered in New York City, it has grown into a key player in the global healthcare market, influencing medical advancements and treatment protocols. Bristol-Myers Squibb is pivotal for its groundbreaking contributions to cancer treatment, particularly through its development of immunotherapy drugs, which alter and assist the immune system's ability to fight cancer cells. Additionally, the firm extends its impacts across multiple sectors, affecting industries such as biotechnology, pharmaceuticals, and healthcare. The company's significance is underscored by its extensive research and development investments, often collaborating with research institutions and academic entities worldwide to pioneer new treatments. Such collaborations expand its influence beyond product distribution to shaping future healthcare landscapes. Bristol-Myers Squibb's commitment to innovation and addressing unmet medical needs makes it a prominent entity in the pharmaceutical sector.